Sym-013

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSym-013

Drug Alias NameSym-013

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSymphogen A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSymphogen A/S

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A